Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
about
Positron emission tomography (PET) in primary prostate cancer staging and risk assessmentThe phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis.PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.Current status of theranostics in prostate cancer.68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review.Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.Prostate-specific membrane antigen radioguided surgery: a promising utility.Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.[The role of PSMA PET-CT in patients with metastatic prostate cancer].Advances in prostate-specific membrane antigen PET of prostate cancer.[The role of PSMA PET-CT in patients with metastatic prostate cancer].Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.MRI and 11C Acetate PET/CT for Prediction of Regional Lymph Node Metastasis in Newly Diagnosed Prostate Cancer.Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy.Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and ChallengesClinical implications of PET/CT in prostate cancer management
P2860
Q33890153-3858F6CF-1A30-418B-BAA4-F75B4924E4ACQ38648799-CD8082C7-FC70-4282-8D29-939DA8FB82D3Q38665724-AADED191-DC1E-481D-873D-E1A1BF7367B9Q38720852-93DCAD00-05A8-46CD-9B09-EF08972FECAFQ38747415-5FCE6C7A-E1FF-4620-B2A3-210900F8C6C3Q39394372-024BA6D1-3A6A-447E-9991-13EA582DFDE5Q42335927-D9CE071C-8E21-440D-B9E4-53E1E9D4301CQ43119026-EDD7AAB2-8C8E-4467-9474-3FAFB84936B0Q47241139-F846D54D-32DD-4ECC-AB7C-FAF6FADF2141Q47269407-1290D4DC-1ACF-4D4E-8DC8-764080204EB6Q47693515-7A5DAB0B-931C-40E5-A6BD-BAF3116CF7FEQ48222301-2005D9D6-C3E7-4B85-A608-64631897F13EQ48263290-A626800E-75BA-423B-8375-A543FC757CBCQ48267598-E4D19D16-8F20-4BC0-9E8F-1A3A64DD9CA9Q48342936-837062D0-FAA9-4E36-9BC3-D0C0B9D10A8EQ48350715-CCAD2071-53D4-4359-9726-0C80FF17DFAAQ48370281-6D8AF2DA-A26C-4164-BB19-F81165ED39A3Q49589359-4A4D7C80-B7B3-4EBD-8316-D102EC7BD43EQ49713199-162C7438-656F-4E3F-B6FF-0C8DAA8F3587Q49981290-FEF0D620-2B27-48BE-B41C-845465144356Q50034009-D12C73D2-D5BC-454C-BA4F-79AD2CE12B93Q55000240-F7E95875-7DDD-4246-9163-FAD8A3BCE4F4Q55112074-B6C47E15-BA6B-4405-8D31-1F24BF298EB3Q55118858-FC80A014-6533-4488-A126-31C84C68D453Q55399763-313B70FB-6F7D-499A-99DF-B022E3D2AABAQ57107208-2DB85871-8ECD-41E1-ACBF-26DBD6E6F0ABQ59137133-6C3767F4-26D1-4902-9FCD-51BEE03BDE88
P2860
Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Prospective evaluation of 68Ga ...... de staging in prostate cancer.
@en
Prospective evaluation of 68Ga ...... de staging in prostate cancer.
@nl
type
label
Prospective evaluation of 68Ga ...... de staging in prostate cancer.
@en
Prospective evaluation of 68Ga ...... de staging in prostate cancer.
@nl
prefLabel
Prospective evaluation of 68Ga ...... de staging in prostate cancer.
@en
Prospective evaluation of 68Ga ...... de staging in prostate cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Prospective evaluation of 68Ga ...... ode staging in prostate cancer
@en
P2093
Pim J van Leeuwen
Quoc Nguyen
Warick Delprado
P2860
P304
P356
10.1111/BJU.13540
P577
2016-06-18T00:00:00Z